Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT

Scott Berry, David Cunningham(Royal Marsden NHS Foundation Trust), M. Mazier(PAREXEL International (France)), Fernando Rivera(Marqués de Valdecilla University Hospital), Eric Van Cutsem(Universitair Ziekenhuis Leuven), M. Michael, Albrecht Kretzschmar(Roche (Switzerland)), Nicolás André(Ben-Gurion University of the Negev)
Journal of Clinical Oncology
May 20, 2008
10.1200/jco.2008.26.15_suppl.4025
Cited by 22

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k